Expanding the Therapeutic Potential of Dual Payload ADCs Through Hydrophilic Linker Technology

• Overcoming the physicochemical limitations of dual payload ADCs with optimized hydrophilic linker technology
• Combining auristatins, Topo1 inhibitors and novel payload modalities while optimizing DAR and payload ratios for efficacy and tolerability
• Achieving deeper and more durable antitumor activity in treatment-resistant solid tumors and hematological malignancies

Speakers:

Juhani Saarinen

Chief Executive Officer

Glykos Finland Oy